FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310106449> ?p ?o ?g. }

• W4310106449 endingPage "8657" @default.
• W4310106449 startingPage "8656" @default.
• W4310106449 abstract "Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease. Parker described three phenotypes: Classic PNH (C-PNH), PNH associated with another bone marrow disorder (BMD-PNH), and subclinical PNH associated with another bone marrow disorder (BMD-SCPNH). Virtually all research of complement inhibitors is focused on C-PNH, while BMD-PNH remains a poorly studied phenotype. The main objective of this study was to analyze survival of BMD-PNH patients compared to that in C-PNH. Methods: This is a multi-center retrospective study. We analyzed the outcomes of patients diagnosed with PNH from March 1990 to January 2022 in three hospitals in Mexico. PNH was classified according to Parker´s criteria. We compared clinical characteristics between patients with C-PNH and BMD-PNH. Univariate and multivariate analyses were performed to assess the impact of PNH phenotype on overall survival and Kaplan Meier curves were plotted to compare survival between groups. Results: We found 106 patients diagnosed with PNH, of which 6 patients with the BMD-SCPNH phenotype were excluded. We analyzed 100 patients, median age 49 years (37.5-59), 50% female, C-PNH 72% (n=72), BMD-PNH 28% (n=28). Relevant differences between groups (C-PNH vs BMD-PNH) include serum LDH median 1,147 vs 256 U/L, p=0.001, LDH ≥1.5 SLN 72.2% vs 26.08%, p=0.001, clone size 78.7% vs 18.8%, and platelets median 120x109 U/L vs 13x109U/L, p=0.0001. In the BMD-PNH group, 46.42% (n=13), had a clone size ≥50%, 7.14% (n=2) presented thrombotic events, and 21.42% (n=6) had high disease burden. Regarding treatment agents (C-PNH vs BMD-PNH), complement inhibitor use was reported in 30.55% (n=22) vs only 3.57% (n=1), p=0.003, and anticoagulation treatment was also more frequent in C-NPH, 47.22% vs 7.14%, p=0.001. Use of bone marrow failure treatment (immunosuppressants and/or androgens) was frequent in the BMD-PNH group, 96.43%, n=27. Table 1 describes pronostic factors found to influence survival. Of note, overall survival of BMD-PNH was considerably lower: median 1y (CI95%; 0-2.4h) vs 10y (CI95%;6.6-13.3y), p=0.012, as presented in Fig 1. In the multivariate analysis, lack of either complement inhibitor (HR 4.64; 95% CI, 1.66-12.94, p=0.003) or lack anticoagulation treatment was independently associated with increased mortality (HR 2.00; 95%CI 1.24-3.25, p=0.005). Conclusions: We found that BMD-PNH patients had a notably inferior survival, and infrequently received agents considered to be standard in C-PNH treatment. Interestingly, 21.42% of BMD-PNH had a high disease burden, a frequent indication of complement inhibitor use in C-PNH. Since specific treatment of BMD-PNH hasn't been defined (that is, beyond immunosuppression and/or androgens), use of complement inhibitor therapy could be a promising option. To our knowledge, clinical trial information of complement inhibitors in BMD-PNH patients is currently lacking. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310106449 created "2022-11-30" @default.
• W4310106449 creator A5019644896 @default.
• W4310106449 creator A5036667880 @default.
• W4310106449 creator A5039340658 @default.
• W4310106449 creator A5040047298 @default.
• W4310106449 creator A5052171614 @default.
• W4310106449 creator A5056280918 @default.
• W4310106449 creator A5069814716 @default.
• W4310106449 creator A5077650231 @default.
• W4310106449 creator A5077803413 @default.
• W4310106449 creator A5091049255 @default.
• W4310106449 date "2022-11-15" @default.
• W4310106449 modified "2023-10-16" @default.
• W4310106449 title "Multi-Center Analysis of Clinical Characteristics, Outcomes and Overall Survival of an Under-Studied Entity: Paroxysmal Nocturnal Hemoglobinuria Associated with Bone Marrow Disorder" @default.
• W4310106449 doi "https://doi.org/10.1182/blood-2022-170818" @default.
• W4310106449 hasPublicationYear "2022" @default.
• W4310106449 type Work @default.
• W4310106449 citedByCount "0" @default.
• W4310106449 crossrefType "journal-article" @default.
• W4310106449 hasAuthorship W4310106449A5019644896 @default.
• W4310106449 hasAuthorship W4310106449A5036667880 @default.
• W4310106449 hasAuthorship W4310106449A5039340658 @default.
• W4310106449 hasAuthorship W4310106449A5040047298 @default.
• W4310106449 hasAuthorship W4310106449A5052171614 @default.
• W4310106449 hasAuthorship W4310106449A5056280918 @default.
• W4310106449 hasAuthorship W4310106449A5069814716 @default.
• W4310106449 hasAuthorship W4310106449A5077650231 @default.
• W4310106449 hasAuthorship W4310106449A5077803413 @default.
• W4310106449 hasAuthorship W4310106449A5091049255 @default.
• W4310106449 hasBestOaLocation W43101064491 @default.
• W4310106449 hasConcept C109159458 @default.
• W4310106449 hasConcept C126322002 @default.
• W4310106449 hasConcept C187212893 @default.
• W4310106449 hasConcept C2777346216 @default.
• W4310106449 hasConcept C2780007613 @default.
• W4310106449 hasConcept C2780525284 @default.
• W4310106449 hasConcept C28328180 @default.
• W4310106449 hasConcept C2909801294 @default.
• W4310106449 hasConcept C54355233 @default.
• W4310106449 hasConcept C71924100 @default.
• W4310106449 hasConcept C86803240 @default.
• W4310106449 hasConceptScore W4310106449C109159458 @default.
• W4310106449 hasConceptScore W4310106449C126322002 @default.
• W4310106449 hasConceptScore W4310106449C187212893 @default.
• W4310106449 hasConceptScore W4310106449C2777346216 @default.
• W4310106449 hasConceptScore W4310106449C2780007613 @default.
• W4310106449 hasConceptScore W4310106449C2780525284 @default.
• W4310106449 hasConceptScore W4310106449C28328180 @default.
• W4310106449 hasConceptScore W4310106449C2909801294 @default.
• W4310106449 hasConceptScore W4310106449C54355233 @default.
• W4310106449 hasConceptScore W4310106449C71924100 @default.
• W4310106449 hasConceptScore W4310106449C86803240 @default.
• W4310106449 hasIssue "Supplement 1" @default.
• W4310106449 hasLocation W43101064491 @default.
• W4310106449 hasOpenAccess W4310106449 @default.
• W4310106449 hasPrimaryLocation W43101064491 @default.
• W4310106449 hasRelatedWork W19206636 @default.
• W4310106449 hasRelatedWork W2075771760 @default.
• W4310106449 hasRelatedWork W2112988637 @default.
• W4310106449 hasRelatedWork W2356827828 @default.
• W4310106449 hasRelatedWork W2370931173 @default.
• W4310106449 hasRelatedWork W2410502920 @default.
• W4310106449 hasRelatedWork W2469075738 @default.
• W4310106449 hasRelatedWork W2500019632 @default.
• W4310106449 hasRelatedWork W2756176868 @default.
• W4310106449 hasRelatedWork W3147733661 @default.
• W4310106449 hasVolume "140" @default.
• W4310106449 isParatext "false" @default.
• W4310106449 isRetracted "false" @default.
• W4310106449 workType "article" @default.